Bench to Bedside to Benefit patients - next generation gene therapies to cure cancer and infectious diseases - with Marco Alessandrini

What if we could engineer our immune cells to efficiently cure any cancer in an efficient and scalable way? What if we could genetically arm and upgrade the immune system to kill cancer and infected cells? The team at Antion Biosciences, a spin-off from University of Geneva, has developed a breakthrough platform that harnesses the power of microRNA gene silencing to create a toolkit to efficiently upgrade the software of T cells to treat a wide range of diseases using healthy donor cells. If you want to know more about the future of gene engineering in the context of allogeneic molecular therapies listen to Marco Alessandrini, the Chief Technical Officer at Antion Biosciences, interviewed by Inês Pinheiro.